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Dyslipidaemia in a Black African diabetic 
population: burden, pattern and predictors
William Lumu1, Leaticia Kampiire2, George Patrick Akabwai3, Richard Ssekitoleko4, Daniel Ssekikubo Kiggundu5 
and Davis Kibirige6*
Abstract 
Objectives: This study sought to assess the burden, pattern and predictors of dyslipidaemia in 425 adult diabetic 
patients in Uganda.
Results: The median (IQR) age of the study participants was 53 (43.5–62) years with a female majority (283, 66.9%). 
Dyslipidaemia defined as presence of ≥ 1 lipid abnormalities was observed in 374 (88%) study participants. Col-
lectively, the predictors of dyslipidaemia were: female gender, study site (private hospitals), type of diabetes (type 
2 diabetes mellitus), statin therapy, increased body mass index and diastolic blood pressure. Proactive screening of 
dyslipidaemia and its optimal management using lipid lowering therapy should be emphasised among adult diabetic 
patients in Uganda.
Keywords: Dyslipidaemia, Burden, Predictors, Adult diabetics, Uganda
© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
Globally, cardiovascular diseases (CVD) account for the 
greatest adult morbidity and mortality. According to the 
2012 World Health Organisation estimates, about 17.5 
million people died from CVD. This was equivalent to 
31% of all global deaths and the majority (about 80%) of 
these deaths occurred in low and middle income coun-
tries [1]. Diabetes mellitus (DM) is a recognised coronary 
artery disease equivalent which accounts for about 75% 
of atherosclerotic related mortality in diabetic patients 
[2]. Diabetic dyslipidaemia is defined by a high plasma 
TGL concentration, low HDL cholesterol concentration 
and increased concentration of small dense LDL-choles-
terol particles [3].
Despite compelling evidence that dyslipidaemia is 
highly prevalent among patients with type 2 diabetes 
mellitus (T2DM), there are few published studies about 
diabetes-dyslipidaemia co-morbidity in Uganda [4–6]. 
These available studies have limitations like: small sam-
ple sizes, being single hospital based, the varying study 
definitions of dyslipidaemia and did not investigate the 
independent predictors of dyslipidaemia.
This study investigated the burden, pattern and predic-
tors of dyslipidaemia in Uganda.
Main text
Methods
This analytical cross sectional study was performed from 
1st September 2014 to 31st July 2015 at outpatient dia-
betic clinics of 3 urban tertiary hospitals in Kampala, 
Uganda. These hospitals serve an urban population of 
approximately 2 million people. The outpatient diabetes 
clinics in these hospitals function only once a week and 
an average of 35 patients are reviewed by either a general 
practitioner or specialist physician. Comprehensive dia-
betic education, body mass index (BMI), blood pressure 
(BP) and fasting blood sugar measurement are regularly 
done at every clinical review.
The patients that were eligible for enrolment in the 
study were those aged ≥ 18 years with a confirmed diag-
nosis of diabetes using either fasting blood glucose levels, 
an oral glucose tolerance test, HbA1c or random blood 
sugar level in the presence of symptoms of diabetes, had 
been receiving treatment at the study centre for a mini-
mum of 6  months and had provided informed consent. 
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These were enrolled consecutively until the desired sam-
ple study size was reached.
All critically ill patients that required intensive care in-
patient management were excluded from the study.
Sample size calculation
Basing on one of the objectives of the study i.e. to deter-
mine the burden of dyslipidaemia, the prevalence (P) 
of low high dense lipoprotein cholesterol (HDLC) 
of  ≤  40  mmol/l of 52% as reported in the study by 
Kamara et al. among 150 adult diabetic patients in South-
ern Western Uganda was used as the prevalence of dys-
lipidaemia [5]. Using the formula: n  =  Z2P (1  −  P)/d2 
where Z (normal value corresponding to the 95% confi-
dence interval) = 1.96, P = 0.52 and d = 0.05, a sample 
size of 383 adult diabetic patients was obtained. However, 
a total of 425 adult patients were enrolled.
Data collection
Using a pre tested questionnaire, information about the 
study participants’ socio-demographic characteristics, 
co-morbidities, type of diabetes, age at diagnosis of DM, 
duration since diagnosis and drug history was collected 
by the trained study team. All study participants had their 
BP, height and weight (for BMI calculation) measured. 
These obtained study variables are known to be associ-
ated with dyslipidaemia in clinical studies and literature.
A venous blood sample was withdrawn from each 
patient after providing informed consent by the study 
phlebotomist for analysis of the glycated haemoglobin 
(HbA1c), low density lipoprotein cholesterol (LDLC), 
HDLC, triglyceride (TGL) and total cholesterol (TC) 
concentrations using a full automated  COBAS® integra 
400 (Roche Diagnostics GmbH) machine at each partici-
pating hospital.
Statistical analysis
The collected study information was entered into Micro-
soft Excel data base and analysed using Stata software 
version 12.1. The patient characteristics of interest were 
reported as frequency and percentage for categorical var-
iables and median and inter-quartile range (IQR) for con-
tinuous variables which were not normally distributed.
Dyslipidaemia was defined as presence of  ≥  1 lipid 
abnormality among the study participants. The following 
lipid concentrations were considered abnormal as accord-
ing to the 2015 American Diabetes Association standards 
of care of diabetes [7] and the 2014 National Lipid Asso-
ciation annual summary of clinical lipidology summary 
on patient-centred evaluation, management and care 
of patients with dyslipidaemia [8]: LDLC  >  2.6  mmol/l, 
HDLC < 1.3 mmol/l, TGL > 1.7 mmol/l, TC > 5 mmol/l 
and non HDLC  <  3.4  mmol/l. Non HDLC, an integral 
lipid parameter in lipidology was calculated using the 
formula: non HDLC  =  TC-HDLC in mmol/l [8]. Fre-
quencies of patients with abnormal concentrations for 
each lipid parameter and those with ≥ 1 lipid abnormal-
ity were calculated to determine the burden and pattern 
of dyslipidaemia. To determine associations between 
the study variables of interest and the 3 abnormal lipid 
parameters of interest i.e. elevated LDLC, TGL and non 
NDLC, bivariate analyses using Chi square test was per-
formed. All variables with a p value of < 0.2 were consid-
ered significant at bivariate analysis. Multivariate analysis 
using logistic regression was then performed to identify 
the independent predictors. A p value of < 0.05 and con-
fidence intervals not including 1 were considered to be 
statistically significant.
Results
Socio‑demographic and clinical characteristics
The median age of the study participants was 53 (43.5–
62) years. Females constituted the greatest proportion 
of study participants (284, 66.9%) and hypertension co-
morbidity was reported in 292 (68.9%) study participants 
(summarised in Table 1).
Burden, pattern, management patterns of dyslipidaemia
Dyslipidaemia was documented in 374 study partici-
pants, accounting for 88%. Elevated LDLC concentrations 
was the commonest single lipid abnormality (60.9%) fol-
lowed by elevated TC (43.1%), TGL (42.1%), non HDLC 
(39.3%) and low HDLC concentrations (29.2%). Severe 
hypertriglyceridemia defined as TGL levels ≥ 5.7 mmol/l 
was noted in only 4 (1%) study participants. Few patients 
were on lipid lowering drugs (LLD) i.e. statins with or 
without fibrates (20.9%) (summarised in Table 1).
Socio‑demographic, clinical and laboratory characteristics 
of the study participants at bivariate analysis
The variables that were statistically associated with the 
elevated lipid parameters of interest are shown in ital-
ics in Tables  2, 3 and Additional file  1: Table S1 and 
Additional file  2: Table S2. Additional file  1: Table S1 is 
uploaded as an additional file.
Independent predictors of elevated LDLC, TGL and non 
HDLC concentrations at multivariate analysis
The following identified independent predictors were 
indentified after logistic regression:
  • Female gender (AOR 2.33 95% CI 1.43–3.80, 
p = 0.001), study site or private hospitals (AOR 0.54 
95% CI 0.32–0.89, p = 0.017), type 2 DM (AOR 4.76 
95% CI 2.03–11.14, p < 0.005), use of statin therapy 
(AOR 0.46 95% CI 0.24–0.90, p = 0.022) and diastolic 
Page 3 of 7Lumu et al. BMC Res Notes  (2017) 10:587 
BP (AOR 1.03 95% CI 1.01–1.05, p = 0.014) for ele-
vated LDLC concentrations.
  • Study site or private hospitals (AOR 0.59 95% CI 
0.37–0.96, p = 0.032) and increased BMI (AOR 1.06 
95% CI 1.02–1.10, p = 0.002) for elevated TGL con-
centrations.
  • Female gender (AOR 2.20 95% CI 1.37–3.53, 
p = 0.001), study site or private hospitals (AOR 0.48 
95% CI 0.29–0.79, p  =  0.004), type 2 DM (AOR 
3.13 95% CI 1.53–6.40, p = 0.002) and use of statin 
therapy (AOR 0.43 95% CI 0.23–0.80, p = 0.008) for 
elevated non HDLC concentrations (summarised as 
Additional file  1: Table S2 which is uploaded as an 
additional file).
Discussion
This cross sectional study shows that dyslipidaemia was 
prevalent in the majority of the surveyed adult diabetic 
population. The rate of use of LLD was also low. The doc-
umented pattern of dyslipidaemia is consistent with what 
is described as diabetic dyslipidaemia [3].
Dyslipidaemia has been documented to be highly 
prevalent in African diabetic patients in most studies [6, 
9–14]. Despite this high prevalence, varied patterns of 
Table 1 Socio-demographic and  clinical characteristics 
of the study participants (N = 425)
Variable N (%)
Age in years, median (IQR) 53 (43.5–62)
Gender, n (%)
 Male 140 (33.02)
 Female 284 (66.98)
Education level, n (%)
 None 38 (8.96)
 Primary 165 (38.92)
 Secondary 141 (33.25)
 Tertiary 79 (18.63)
Occupation, n (%)
 Employed 212 (50)
 Unemployed 212 (50)
Marital status, n (%)
 Married 259 (61.08)
 Cohabiting 10 (2.36)
 Single 47 (11.08)
 Divorced 41 (9.67)
 Widow/widowed 67 (15.80)
Place of residence
 Rural 136 (32.08)
 Urban 288 (67.92)
Study site
 Government 199 (46.82)
 Private 226 (53.18)
Smoking
 Yes 10 (2.35)
 No 415 (97.65)
Known HT
 Yes 292 (68.87)
 No 132 (31.13)
HIV co-existent
 Yes 17 (4.00)
 No 408 (96.00)
FH-DM
 Yes 264 (62.26)
 No 160 (37.74)
Type of DM
 Type 1 DM 55 (13.13)
 Type 2 DM 364 (86.87)
Drug history
 Diet alone 3 (0.71)
 Metformin alone 79 (18.59)
 Met + SU 127 (29.88)
 Met + SU + TZD 16 (3.76)
 Met + incretins 8 (1.88)
 Insulin alone/+ met 188 (44.34)
 Statins 89 (20.94)
Table 1 continued
Variable Median (IQR), N = 425
Age at diagnosis in years 47 (37–55)
Duration with DM in years 4.5 (2–10)
BMI in kg/m2 27 (23–30.6)
HbA1c (%) 9 (6.8–12.4)
LDLC in mmol/l 2.9 (2.3–3.84)
HDLC in mmol/l 1.19 (0.9–1.42)
TC in mmol/l 4.82 (4.1–5.71)
TGL in mmol/l 1.6 (1.23–2.2)
LDLC > 2.6 mmol/l 259 (60.9)
TC > 5 mmol/l 183 (43.1)
HDLC < 1 mmol/l 124 (29.2)
TGL > 1.7 mmol/l 179 (41.2)
TGL ≥ 5.7 mmol/l 5 (1.2)
Non HDLC < 3.4 mmol/l 167 (39.3)
TC/HDLC ratio < 4.5 mmol/l 235 (55.3)
All normal LDLC, TGL, TC and HDLC concentra-
tions
5 (12)
SBP, mmHg 139 (124–155)
DBP, mmHg 80 (73–91)
DM diabetes mellitus, HT hypertension, FH family history, SU sulphonylureas, 
Met metformin, TZD thiazolididiones, BMI body mass index, HbA1c glycated 
haemoglobin, LDLC low density lipoprotein cholesterol, HDLC high density 
lipoprotein cholesterol, TC total cholesterol, TGL triglycerides, SBP systolic blood 
pressure, DBP diastolic blood pressure, IQR inter quartile range
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dyslipidaemia have been described among African dia-
betic patients. A study done in a university referral hos-
pital in Southern Ethiopia among 295 diabetics reported 
low HDLC concentration to be the most prevalent lipid 
abnormality (87.8%), followed by increased LDLC con-
centrations (63.7%), increased TC (34.6%) and increased 
TGL (29.8%) [9]. A similar pattern of dyslipidaemia was 
also noted in a small South African urban study of 150 
Table 2 Suboptimal LDLC concentrations in relation to socio-demographic and clinical characteristics at bivariable analy-
sis
DM diabetes mellitus, HT hypertension, FH family history, OHA oral hypoglycaemic agents, BMI body mass index, HbA1c glycated haemoglobin, SBP systolic blood 
pressure, DBP diastolic blood pressure
Characteristic LDLC > 2.6 mmol/l LDLC ≤ 2.6 mmol/l OR 95% CI p value
Age, median (IQR) 55.5 (48–67) 53 (43–62) 1.01 (0.99–1.02) 0.224
Gender
 Male 71 (51.45) 67 (49.55) 1 0.001
 Female 188 (68.12) 88 (31.88) 2.02 (1.33–3.07)
Type of hospital
 Government 133 (66.83) 66 (33.17) 1 0.084
 Private 126 (58.60) 89 (41.40) 0.76 (0.47–1.05)
Place of residence
 Rural 85 (62.96) 50 (37.04) 1 0.906
 Urban 174 (62.37) 105 (37.63) 0.97 (0.64–1.49)
Smoking
 Smoker 8 (88.89) 1 (11.11) 1 0.135
 Non smoker 251 (61.98) 154 (38.02) 0.20 (0.03–1.64)
Occupation
 Employed 132 (64.08) 74 (35.92) 1 0.526
 Unemployed 127 (61.06) 81 (38.94) 0.88 (0.59–1.31)
Co-existing HT
 Yes 191 (67.25) 93 (32.75) 1 0.004
 No 68 (52.31) 62 (47.69) 0.53 (0.35–0.82)
DM type
 Type 1 DM 21 (38.18) 34 (61.82) 1 <0.005
 Type 2 DM 234 (66.10) 120 (33.90) 3.16 (1.76–5.68)
Family history of DM
 Yes 170 (66.15) 87 (33.85) 1 0.054
 No 89 (56.69) 68 (43.31) 0.67 (0.45–1.01)
HIV co-morbidity
 Yes 10 (58.82) 7 (41.18) 1 0.745
 No 249 (62.72) 148 (37.28) 1.18 (0.44–3.16)
Median (IQR) age at diagnosis 53.5 (49–58) 46 (37–55) 1.01 (0.99–1.02) 0.379
 Median (IQR) years duration with DM. 3.5 (1–14) 4.5 (2–10) 1.02 (0.99–1.06) 0.165
 BMI in kg/m2 median (IQR) 28.7 (25–34.3) 27 (23–30.6) 1.04 (1.00–1.07) 0.041
BP in mmHg, median (IQR)
 SBP 130 (20–150) 139 (24–156) 1.01 (1.00–1.02) 0.015
 DBP 70 (70–78) 80 (74–91) 1.02 (1.01–1.04) 0.002
 HbA1c (%), median (IQR) 8.95 (6.8–10.1) 9 (6.9–12.4) 0.98 (0.93–1.03) 0.488
Drugs
 Insulin therapy 106 (58.89) 74 (41.11) 1 0.113
 On OHA 151 (66.52) 76 (33.48) 1.39 (0.92–2.08)
Statin therapy n (%)
 No 199 (60.86) 128 (39.14) 1 0.166
 Yes 60 (68.97) 27 (31.03) 0.70 (0.42–1.16)
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adult diabetic patients (low HDLC-60.7%, increased 
LDLC-49.3%, increased TGL-45.3% and increased 
TC-29.3%) [11]. Results from the diabetes care study in 
Nigeria (Diabcare Nigeria study) in 531 diabetic patients 
reported low HDLC (76.3%) and increased TGL (60.7%) 
as the predominant lipid abnormalities [12]. The largest 
study assessing quality of diabetes care in 6 sub Saha-
ran African countries (Diabcare Africa study) reported 
Table 3 Suboptimal non HDLC concentrations in relation to socio-demographic and clinical characteristics at bivariable 
analysis
DM diabetes mellitus, HT hypertension, FH family history, OHA oral hypoglycaemic agents, BMI body mass index, HbA1c glycated haemoglobin, SBP systolic blood 
pressure, DBP diastolic blood pressure
Characteristic Non HDLC ≥ 3.4 mmol/l Non HDLC < 3.4 mmol/l OR 95% CI p value
Age, median (IQR) 56 (48–67) 53 (43–61) 1.02 (1.01–1.04) 0.001
Gender
 Male 65 (47.10) 73 (52.90) 1 <0.005
 Female 181 (65.82) 94 (34.18) 2.16 (1.43–3.28)
Type of hospital
 Government 126 (63.32) 73 (36.68) 1 0.134
 Private 120 (56.07) 94 (43.93) 0.74 (0.50–1.10)
Place of residence
 Rural 85 (63.43) 49 (36.57) 1 0.267
 Urban 161 (57.71) 118 (42.29) 0.79 (0.51–1.20)
Smoking
 Smoker 6 (66.67) 3 (33.33) 1 0.662
 Non smoker 240 (59.41) 167 (40.44) 0.73 (0.18–2.97)
Occupation
 Employed 122 (59.22) 84 (40.78) 1 0.888
 Unemployed 124 (59.90) 83 (40.10) 1.03 (0.69–1.52)
Co-existing HT
 Yes 179 (63.25) 104 (36.75) 1 0.025
 No 67 (51.54) 63 (48.46) 0.62 (0.41–0.94)
DM type
 Type 1 DM 16 (29.09) 39 (70.91) 1 <0.005
 Type 2 DM 227 (64.31) 126 (35.69) 4.39 (2.36–8.17)
Family history of DM
 Yes 162 (63.04) 95 (36.96) 1 0.066
 No 84 (53.85) 72 (46.15) 0.68 (0.46–1.02)
HIV co-morbidity
 Yes 9 (52.94) 8 (47.06) 1 0.571
 No 237 (59.85) 159 (40.15) 1.32 (0.50–3.51)
Median age at diagnosis 53 (48–58) 46 (37–55) 1.03 (1.01–1.04) 0.001
Median (IQR) years duration with DM. 6 (1–15) 4 (2–10) 1.02 (0.99–1.05) 0.265
BMI in kg/m2 median (IQR) 28.7 (25–34.3) 27 (23–30.6) 1.07 (1.03–1.11) <0.005
BP in mmHg, median (IQR)
 SBP 130 (120–150) 139 (124–156) 1.01 (1.00–1.02) 0.020
 DBP 70 (70–78) 80 (74–91) 1.02 (1.01–1.03) 0.008
 HbA1c (%) 9.2 (6.8–10.1) 9 (6.85–12.4) 1.00 (0.95–1.05) 0.967
Drugs
I nsulin therapy 94 (52.22) 86 (47.78) 1 0.005
 On OHA 149 (65.93) 77 (34.07) 1.77 (1.18–2.65)
On statin therapy n (%)
 Yes 184 (56.44) 142 (43.56) 1 0.013
 No 62 (71.26) 25 (28.74) 0.52 (0.31–0.87)
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suboptimal TC and HDL concentrations in 36.2 and 
39.4% of the study participants respectively. No study 
participant had elevated TGL concentrations despite the 
high prevalence of suboptimal glycaemic control (71% 
having HbA1c ≥ 6.5%) [13].
In our study, increased LDLC concentrations was the 
most prevalent, followed by elevated TC, TGL and low 
HDLC concentrations. Severe TGL defined as concen-
trations  ≥  5.7  mmol/l were uncommon in our study 
population.
Several reasons could explain the high prevalence of 
dyslipidaemia reported in our study and other similar 
African studies. Low rates of screening for dyslipidaemia 
and use of LLD have been noted in the majority of the 
sub Saharan African countries, possibly due to knowl-
edge gaps among clinicians, low access to LLD and 
prohibitive costs of LLD and lipid profile testing. Two 
retrospective chart based studies done in outpatient dia-
betic clinics in Uganda [6] and South Africa [14] reported 
only 14 and 26% of the study participants having ever 
done a lipid profile assessment at least once in the previ-
ous 12 months and only 20.4 and 26.2% of the study par-
ticipants respectively were receiving LLD. The Diabcare 
Africa study reported that about 45% of the study par-
ticipants had ever performed a lipid profile assessment at 
least once in the past 1 year and only 13% were on LLD 
[13]. The LLD were reported to be unaffordable by simi-
lar studies performed in Cameroon [15] and in Benin, 
Sudan and Eriteria [16] reported LLD.
Predictors of abnormal LDLC, TGL and non HDLC 
concentrations
Female gender, having type 2 DM, increased BMI and 
diastolic BP increased the likelihood of having abnormal 
LDLC, TGL and non HDLC concentrations while the use 
of LLD and receiving diabetes care from a private hospi-
tal reduced the likelihood.
An increased rate of dyslipidaemia among female dia-
betic patients has also been reported by studies per-
formed in Ethiopia [9] and Botswana [10]. Compelling 
evidence suggests that dyslipidaemia is a common meta-
bolic abnormality in type 2 DM compared to type 1 DM 
and in obese or overweight patients. Increased diastolic 
BP or hypertension and type 2 DM is part of the intimate 
cluster of metabolic disorders in metabolic or insulin 
resistance syndrome [3].
Unequivocal evidence supports the use of lifestyle 
modification and LLD in the management of dyslipidae-
mia among adult diabetic patients [3].
Conclusions and recommendations
Dyslipidaemia is frequent among these adult diabetic 
patients in Uganda. The frequency of use of LLD was 
low. Due to this documented high prevalence, proac-
tive screening for dyslipidaemia among adult diabetic 
patients should be encouraged. In addition to encourag-
ing lifestyle measures, it is imperative that ready access to 
affordable lipid lowering drugs for optimal management 
of dyslipidaemia is improved in Uganda.
Limitations
We cannot generalise these findings to the entire adult 
diabetic population in Uganda because the study was 
only done in urban tertiary health centres.
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